← The Wire
NAGENasdaq
Niagen Bioscience, Inc.
Medicinal Chemicals & Botanical Products · DE · CIK 1386570
Niagen Bioscience, Inc. develops and commercializes NAD+ precursors for healthy aging
$275M
Market cap
$3.30
Last close
-3.5%
1D
-3.2%
5D
703K
Volume
Price · last 39 sessions-33.1%
May 4L $3.30 · H $4.97Jun 29
371
Total filings
Jun 29, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 29, 20268-KResults of Operations · Reg FD DisclosureMay 6, 202610-Q10-QMay 6, 2026DEFA14ADEFA14AApr 29, 2026DEF 14ADEF 14AApr 29, 20268-KCompany UpdateMar 19, 20268-KResults of Operations · Reg FD DisclosureMar 4, 202610-K10-KMar 4, 20268-KReg FD Disclosure · Company UpdateFeb 26, 20268-KMaterial Agreement · Reg FD DisclosureDec 22, 20258-KCompany UpdateNov 6, 20258-KResults of Operations · Reg FD DisclosureNov 4, 202510-Q10-QNov 4, 20258-KReg FD DisclosureOct 6, 20258-KResults of Operations · Reg FD DisclosureAug 6, 202510-Q10-QAug 6, 20258-KMaterial AgreementJul 29, 20258-KExecutive Change · Shareholder VoteJun 27, 20258-KResults of Operations · Reg FD DisclosureMay 7, 202510-Q10-QMay 7, 2025DEFA14ADEFA14AApr 29, 2025DEF 14ADEF 14AApr 29, 20258-KBylaw Amendment · Reg FD DisclosureMar 19, 20258-KResults of Operations · Reg FD DisclosureMar 4, 202510-K10-KMar 4, 20258-KExecutive ChangeFeb 27, 20258-KAuditor ChangeDec 16, 20248-KCompany UpdateDec 4, 20248-KMaterial AgreementNov 21, 20248-KResults of Operations · Reg FD DisclosureOct 31, 202410-Q10-QOct 31, 20248-KAuditor ChangeOct 11, 20248-KExecutive ChangeSep 20, 20248-KResults of Operations · Reg FD DisclosureAug 7, 202410-Q10-QAug 7, 20248-KExecutive ChangeJul 16, 20248-KExecutive ChangeJun 25, 20248-KShareholder VoteJun 24, 20248-KResults of Operations · Reg FD DisclosureMay 8, 202410-Q10-QMay 8, 2024DEFA14ADEFA14AApr 25, 2024DEF 14ADEF 14AApr 25, 20248-KResults of Operations · Reg FD DisclosureMar 6, 202410-K10-KMar 6, 20248-KMaterial Agreement · New Debt / ObligationDec 13, 20238-KResults of Operations · Reg FD DisclosureNov 8, 202310-Q10-QNov 8, 20238-KResults of Operations · Reg FD DisclosureAug 9, 202310-Q10-QAug 9, 2023424B5PROSPECTUS SUPPLEMENTJul 6, 20238-KExecutive Change · Shareholder VoteJun 20, 20238-KResults of Operations · Reg FD DisclosureMay 10, 202310-Q10-QMay 10, 2023DEFA14ADEFA14AApr 28, 2023DEF 14ADEF 14AApr 28, 20238-KBylaw AmendmentMar 17, 20238-KResults of Operations · Reg FD DisclosureMar 8, 202310-K10-KMar 8, 20238-KExecutive ChangeJan 5, 202310-Q10-QNov 2, 20228-KResults of Operations · Reg FD DisclosureNov 2, 2022SC 13GSC 13GOct 19, 2022424B5FORM 424B5Oct 11, 20228-KMaterial Agreement · Reg FD DisclosureOct 11, 20228-KMaterial Agreement · Agreement TerminatedOct 3, 202210-Q10-QAug 10, 20228-KExecutive Change · Results of OperationsAug 10, 20228-KShareholder Vote · Company UpdateJun 21, 20228-KExecutive ChangeJun 9, 20228-KMaterial Agreement · Reg FD DisclosureMay 19, 20228-KResults of Operations · Reg FD DisclosureMay 12, 202210-Q10-QMay 12, 2022DEFA14ADEFA14AApr 27, 2022DEF 14ADEF 14AApr 27, 20228-KExecutive ChangeApr 18, 20228-KExecutive ChangeApr 15, 20228-KExecutive ChangeApr 11, 20228-KExecutive ChangeApr 8, 20228-KReg FD DisclosureMar 23, 202210-K10-KMar 14, 2022
Insider Activity
In the 90 days to Nov 14, 2025: 1 insider bought $46K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 14, 2025 | Pamir OzanChief Financial Officer | Buy | 4,465 | $6.81 | $30K |
| Nov 14, 2025 | Pamir OzanChief Financial Officer | Buy | 2,220 | $6.85 | $15K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance